The Role of Thromboelastography in a Patient on Defibrotide Therapy with Abnormal Coagulation Studies Joanna Lynn Wigfield, D.O., Dana Salzberg, MD, Niketa C. Shah, MD, Holly Miller, MD, Kyrie Magee, CPNP, MSN, RN, Kristen Beebe, MS, PA-C, Roberta H. Adams, MD, Leon Su, M.D. Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S295-S296 (March 2016) DOI: 10.1016/j.bbmt.2015.11.754 Copyright © 2016 Terms and Conditions
Figure 1 TEG during defibrotide therapy with corresponding abnormal RCT. A) At initial diagnosis of SOS B) Post transfusion with TEG normalization prior to defibrotide therapy C) Coagulopathy that developed day +13 demonstrated by abnormal TEG and RCT D) Corrected TEG but persistent abnormal RCT following plasma transfusion Biology of Blood and Marrow Transplantation 2016 22, S295-S296DOI: (10.1016/j.bbmt.2015.11.754) Copyright © 2016 Terms and Conditions